Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 4, 2026, 8:54 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1609–1632 of 1,719 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: Positive control Clear all

Conditions: Substance Use, Unsafe Sexual Behavior
Interventions: Familias Unidas; Behavioral
Lead sponsor: University of Miami; Other
Eligibility: 12 Years to 17 Years
Enrollment: 242 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2009 – 2011
U.S. locations: 1
States / cities: Miami, Florida

Conditions: Obesity, Diabetes
Interventions: TSSC, TSSC Randomized Behavioral Intervention for weight loss; Behavioral
Lead sponsor: The University of Texas Health Science Center, Houston; Other
Eligibility: 18 Years to 75 Years
Enrollment: 3,100 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2003 – 2013
U.S. locations: 1
States / cities: Brownsville, Texas

Conditions: Metastatic Breast Cancer
Interventions: Belzutifan, Fulvestrant, Everolimus, Exemestane; Drug
Lead sponsor: Merck Sharp & Dohme LLC; Industry
Eligibility: 18 Years and older
Enrollment: 120 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2028
U.S. locations: 14
States / cities: Goodyear, Arizona • Beverly Hills, California • La Jolla, California + 11 more

Conditions: Neuromyelitis Optica and Neuromyelitis Optica Spectrum Disorders
Interventions: Inebilizumab, Placebo; Drug · Other
Lead sponsor: MedImmune LLC; Industry
Eligibility: 18 Years and older
Enrollment: 231 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2020
U.S. locations: 19
States / cities: Birmingham, Alabama • Sacramento, California • San Francisco, California + 16 more

Conditions: Sustained Positive Emotions, Sustained Positive Behavior Change
Interventions: Oxytocin, Placebo (for oxytocin), Lovingkindness Meditation, Mindfulness Meditation; Drug · Behavioral
Lead sponsor: University of North Carolina, Chapel Hill; Other
Eligibility: 35 Years to 64 Years
Enrollment: 239 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2013 – 2014
U.S. locations: 1
States / cities: Chapel Hill, North Carolina

Conditions: Depression, Unipolar, Fall
Interventions: Behavioral Activation, Fall Prevention, Telephone support; Behavioral · Other
Lead sponsor: University of Texas at Austin; Other
Eligibility: 50 Years to 100 Years
Enrollment: 320 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2026
U.S. locations: 1
States / cities: Austin, Texas

Conditions: Healthy
Interventions: ODV Placebo (Matching 25 mg ODV), ODV Placebo (Matching 200 mg ODV), ODV Placebo (Matching 125 mg ODV), ODV Placebo (Matching 100 mg ODV), SMV Placebo (Matching 150 mg SMV), AL-335 Placebo (matching 1200 mg AL-335), Moxifloxacin Placebo (matching 400 mg moxifloxacin), ODV 25 mg, ODV 200 mg, ODV 125 mg, ODV 100 mg, SMV 150 mg, AL-335 1200 mg; Drug
Lead sponsor: Janssen Research & Development, LLC; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 59 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2017
U.S. locations: 1
States / cities: Tempe, Arizona

Conditions: Depression, Anxiety, Suicidal Ideation, Stress, Trauma
Interventions: Trauma-Informed Yoga; Other
Lead sponsor: Montana State University; Other
Eligibility: 14 Years to 19 Years
Enrollment: 47 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021
U.S. locations: 1
States / cities: Bozeman, Montana

Conditions: HIV Infections
Interventions: Nelfinavir mesylate, Efavirenz; Drug
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 3 Months to 16 Years
Enrollment: 103 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 1997 – 2002
U.S. locations: 25
States / cities: Long Beach, California • Los Angeles, California • Oakland, California + 16 more

Conditions: Reward Value Level
Interventions: Socially Evaluated Cold Pressor Task (SECPT), Non-Stressful Control Task; Behavioral
Lead sponsor: NYU Langone Health; Other
Eligibility: 18 Years to 65 Years
Enrollment: 200 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2025 – 2028
U.S. locations: 1
States / cities: New York, New York

Conditions: Influenza, Vaccination
Interventions: Behavioral economics framed test messaging; Behavioral
Lead sponsor: Kaiser Permanente; Other
Eligibility: 6 Months and older
Enrollment: 100,000 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2026
U.S. locations: 1
States / cities: Aurora, Colorado

Conditions: Lyme Disease
Interventions: Skin biopsy, Blood draw, Xenodiagnosis; Procedure · Device
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years and older
Enrollment: 72 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2022
U.S. locations: 5
States / cities: Storrs, Connecticut • Bethesda, Maryland • Boston, Massachusetts + 2 more

Conditions: Substance Use, Stress, Relation, Interpersonal, Bullying, Victimisation, Mental Health Issue, Sleep, Inadequate, Social Skills
Interventions: PeerLearning.net; Behavioral
Lead sponsor: Oregon Research Behavioral Intervention Strategies, Inc.; Industry
Eligibility: Not listed
Enrollment: 924 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021 – 2022
U.S. locations: 1
States / cities: Eugene, Oregon

Conditions: Oxygen Desaturation, Apnea (Central and Obstructive), Airway Obstruction
Interventions: Breath-synchronized oxygen, CPAP, Control; Device
Lead sponsor: University of Utah; Other
Eligibility: 18 Years and older
Enrollment: 280 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2026
U.S. locations: 1
States / cities: South Jordan, Utah

Conditions: Preterm Neonates
Interventions: Gradual weaning from Nasal CPAP in preterm neonates; Procedure
Lead sponsor: Maimonides Medical Center; Other
Eligibility: 24 Weeks to 32 Weeks
Enrollment: 56 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2009
U.S. locations: 1
States / cities: Brooklyn, New York

Conditions: Metastatic Breast Cancer
Interventions: Palbociclib, Fulvestrant, Placebo; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years and older · Female only
Enrollment: 521 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2022
U.S. locations: 134
States / cities: Birmingham, Alabama • Daphne, Alabama • Mobile, Alabama + 90 more

Conditions: Hyperemesis Gravidarum
Interventions: Metformin Extended Release Oral Tablet; Drug
Lead sponsor: University of Southern California; Other
Eligibility: 18 Years to 49 Years · Female only
Enrollment: 224 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2026 – 2031
U.S. locations: 2
States / cities: Birmingham, Alabama • Los Angeles, California

Conditions: Chronic Pelvic Pain
Interventions: Not listed
Lead sponsor: Northwestern University; Other
Eligibility: 21 Years to 80 Years · Male only
Enrollment: 11 participants
Timeline: 2021 – 2023
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: Respiration Failure, Cardio Vascular Disease, Cardiogenic Pulmonary Oedema, Critical Illness, Mechanical Ventilation, Cardiogenic Shock, Cardiopulmonary
Interventions: Volume Controlled Mode, Pressure Controlled Mode; Other
Lead sponsor: Mayo Clinic; Other
Eligibility: 18 Years and older
Enrollment: 75 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2027
U.S. locations: 1
States / cities: Rochester, Minnesota

Conditions: Non-small Cell Lung Cancer
Interventions: Osimertinib (AZD9291) pemetrexed cisplatin or carboplatin, Placebo for osimertinib (AZD9291) pemetrexed cisplatin or carboplatin; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years to 130 Years
Enrollment: 98 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2027
U.S. locations: 2
States / cities: Silver Spring, Maryland • Boston, Massachusetts

Conditions: Cancer Nos
Interventions: Resting Energy Expenditure, Thermal Comfort Questionnaire; Procedure · Other
Lead sponsor: Virginia Commonwealth University; Other
Eligibility: 40 Years and older
Enrollment: 3 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2020
U.S. locations: 1
States / cities: Richmond, Virginia

Conditions: Schizophrenia, Schizoaffective Disorder
Interventions: Pravastatin; Drug
Lead sponsor: University of Pittsburgh; Other
Eligibility: 18 Years to 65 Years
Enrollment: 72 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2003 – 2007
U.S. locations: 1
States / cities: Pittsburgh, Pennsylvania

Conditions: Traumatic Brain Injury, Head Injury, Head Injuries, Closed, Brain Hemorrhage, Traumatic, Brain Edema, Intracranial Edema
Interventions: Road-to-recovery; Behavioral
Lead sponsor: Children's Hospital Medical Center, Cincinnati; Other
Eligibility: 18 Years and older
Enrollment: 200 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2026
U.S. locations: 1
States / cities: Cincinnati, Ohio

Conditions: HER2-positive Breast Cancer, Advanced Breast Cancer
Interventions: Prolonged Overnight Fasting, Moderate-Intensity Exercise, General Health Education Sessions; Behavioral
Lead sponsor: University of Miami; Other
Eligibility: 18 Years and older · Female only
Enrollment: 260 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2029
U.S. locations: 3
States / cities: Phoenix, Arizona • Miami, Florida • Boston, Massachusetts

Search by objective public record fields.

Familias Unidas: Preventing Drug Abuse and HIV in Hispanic First Offenders

Tu Salud Si Cuenta Media Campaign

Study of Belzutifan (MK-6482) Plus Fulvestrant for ER+/HER2- Metastatic Breast Cancer (MK-6482-029/LITESPARK-029)

N-MOmentum: A Clinical Research Study of Inebilizumab in Neuromyelitis Optica Spectrum Disorders

Study of Wellness Behaviors as a Function of Oxytocin vs Placebo

Integrated Tele-Behavioral Activation and Fall Prevention for Low-income Homebound Seniors With Depression

A Study to Evaluate the Cardiac Safety of a Single Dose of AL-335 Administered on a Background of Simeprevir and Odalasvir and of Repeated Doses of Odalasvir Administered Alone in Healthy Participants

A Trauma-Informed Approach for Positive Youth Development for Montana Students

Safety, Tolerability, and Anti-HIV Activity of DMP 266 (Efavirenz) in Combination With Nelfinavir in HIV-Positive Children

Stress and Anxiety Effects on Valuation

Kaiser Colorado Flu Nudge

Xenodiagnosis After Antibiotic Treatment for Lyme Disease

Automating Peer Learning to Reduce Alcohol Use and Related Deviant Behavior in Secondary School

Supplemental Oxygen and Oxygen Desaturations in Colonoscopies

Trial of Weaning of Nasal Continuous Positive Airway Pressure (CPAP)

Palbociclib (PD-0332991) Combined With Fulvestrant In Hormone Receptor+ HER2-Negative Metastatic Breast Cancer After Endocrine Failure (PALOMA-3)

Hyperemesis Gravidarum Risk Reduction With Metformin

Effects of Epigenetic Regulation in Chronic Pelvic Pain Syndrome

COMPARE-VENT Feasibility Pilot Study

A Study to Evaluate Chemotherapy Plus Osimertinib Against Chemotherapy Plus Placebo in Patients With Non-small Cell Lung Cancer (NSCLC)

Maladaptive Adipose Tissue Activity in Cancer

Improving Symptoms of Schizophrenia and Schizoaffective Disorder by Supplementing Medications With Pravastatin

Setting Families on a Positive Path to Recovery After Pediatric TBI: Road-to-Recovery

Prolonged Overnight Fasting and/or Exercise on Fatigue and Other Patient Reported Outcomes in Women With Hormone Receptor Positive Advanced Breast Cancer